Outcome data comparing patients with multiple primary invasive cutaneous malignant melanomas (MPMs) to single primary invasive cutaneous malignant melanomas (SPMs) show conflicting results. We have analyzed differences in disease-specific survival between these patients in a nationwide population-based setting. From the Swedish Melanoma Register, 27,235 patients were identified with a first invasive cutaneous malignant melanoma (CMM) between 1990 and 2007, followed-up through 2013. Of these, 700 patients developed MPMs. Cox proportional hazard regression was used for adjusted cause-specific hazard ratios (HRs). An interval of 5 years between CMM diagnoses was significantly correlated to a decreased CMM-specific survival in Stage I-II MPM-vs. SPM-patients (HR 1.32; 95% CI 1.04-1.67; p 5 0.02). MPM-patients with longer time interval between diagnoses experienced similar risk of CMM-death as SPM-patients. The risk of CMM-death increased by almost 50% above the expected outcome according to stage of the index CMM by the diagnosis of a second CMM (HR 1.48; 95% CI 1.19-1.85; p < 0.001). MPM vs. SPM-patients had a worse outcome (HR 1.38; 95% CI 1.05-1.83; p 5 0.001). This emphasizes the importance of prevention efforts in SPM-patients to decrease the risk of subsequent CMMs and has implications for more vigilant follow-up in MPM-patients.
data, tumor characteristics, surgical management and followup for almost 50,000 CMM patients, covering 98% of all CMMs diagnosed in Sweden. 19, 20 We linked data to several continuously updated population-based, nationwide registers by using the unique 10-digit Swedish identity number. [21] [22] [23] [24] [25] 
Patient cohort
Between 1990 and 2007, 37,739 patients were identified with a primary CMM in SMR. All in situ CMMs (n 5 9,292) and patients with invasive CMMs before 1990 (n 5 512) were excluded. The cohort included 27,235 patients with a first primary invasive CMM. Of these, 700 patients eventually developed additional primary invasive CMMs. In all analyses, patients were defined as SPM-patients until the date of a second CMM and were then reclassified as MPMpatients.
Study variables
Individual information on sex, age at diagnosis, period of diagnosis, tumor site, disease stage at diagnosis, tumor (T)-class, tumor ulceration, Clark's level of invasion, and health care region was obtained from the SMR. Histopathologic characteristics were classified according to the 2002 American Joint Committee on Cancer system, which was used during the study period. 26 Level of education at the time of diagnosis of the first primary (index) CMM was classified as low 9 years, intermediate 10-12 years and high 13 years. Cohabitation status was categorized as living with a partner vs. living alone at the time of diagnosis of the index CMM. 27 Living area was grouped as metropolitan: >200,000 inhabitants; urban: 50,000-200,000 inhabitants; rural: <50,000 inhabitants.
Statistical analyses
First, we analyzed how the CMM-prognosis differed between MPM-and SPM-patients to have a tool for prognostication of patients that have been diagnosed with a second CMM. We adjusted for confounders (i.e., sex, age, level of education, cohabitation status, living area, period of diagnosis) at the time of the second CMM and for both confounders and mediators (i.e., tumor thickness, Clark's level of invasion, tumor ulceration, tumor site and disease stage) at the time of diagnosis of the most advanced CMM for MPM-patients in the survival analysis of MPM-and SPM-patients. The analyses were stratified for health care region. Survival time for MPM-patients was calculated from the date of the second CMM until death, emigration or end of follow-up. MPM-patients with non-synchronous tumors were therfore included twice in the analysis, and the survival time for each patient included both time as SPMpatient and time as MPM-patient. The most advanced tumor was considered index CMM in MPM-patients with synchronous tumors, i.e., simultaneous tumors diagnosed at the same date. SPM-patients were observed from the date of diagnosis until death, emigration, a second CMM or end of follow-up (Dec 31, 2013), whichever occurred first. MPM-patients were grouped into early (5 years interval from index CMM) and late cases (>5 years after the index CMM) and compared with the SPM-group. The CMMspecific survival was compared directly between MPMpatients with a second CMM 5/>5 years, respectively, after their index CMM.
Second, to investigate the additional risk of subsequent CMMs, we also analyzed the effect on the CMM-prognosis by the diagnosis of a second CMM in patients with a SPM. A Cox model was used and the occurrence of second CMM was defined as a time-dependent covariate. The model was adjusted as above for confounders and mediators at the time of the first CMM including histopathologic variables of this CMM. Also, a time-fixed Cox model was conducted, which was similar to the time-dependent analysis, but without a time-dependent variable. In this analysis, again the model was adjusted at the time of the index CMM and for histopathologic characteristics of this CMM as above. The risk of being diagnosed with a second CMM was evaluated with a Cox analysis adjusted for confounders and mediators described above. The Cox analyses only included patients with complete data on all variables. Age-and sex-specific cumulative risks of having a second CMM were calculated. In this analysis, patients were observed from the date of the first CMM until death, emigration, a second CMM or end of follow-up (Dec 31, 2013), whichever occurred first. Patients were censored at the time of death, emigration or end-of follow-up and no competing risk method were used.
In all descriptive statistical analyses, categorical variables were evaluated by v 2 tests and median values with a median test. All statistical analyses were performed using SPSS Version 22.0 (IBM, Armonk, NY).
What's new?
Patients with cutaneous malignant melanoma (CMM) are at risk of developing additional primary invasive cutaneous malignant melanomas (MPMs). Increased survival times likely influence this risk, though associations with disease stage and prognosis remain unclear. In this study, a relatively short time interval (5 years) between diagnoses in stage I-II MPM patients was associated with decreased CMM-specific survival. Prognosis was better for MPM patients with longer intervals between diagnoses and for patients with single primary invasive cutaneous malignant melanoma. Diagnosis of a second CMM, however, increased the risk of CMM death by nearly 50% above the expected outcome. 
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Results

Patient and tumor data of MPM-compared to SPM-patients
Clinical characteristics at the diagnosis of the index CMM in SPM-(n 5 26,535) and MPM-patients (n 5 700) diagnosed in Sweden 1990-2007 are described in Table 1 . MPM-patients were significantly older at diagnosis of their index CMM compared to SPM-patients with a median age of 64 years compared to 62 years for SPM-patients (p < 0.001). A significantly higher proportion of MPM-patients were males compared to SPMpatients (60.4% vs. 48.9%, p < 0.001). A higher proportion of MPM-patients were living with a partner at the time of the diagnosis (67.6% vs. 61.4%, p 5 0.001). The majority of the MPM-patients were diagnosed with two CMMs. Only 11% of the MPM-patients had >2 CMMs (Supporting Information  Table S1 ). The median interval between diagnosis of the first and second CMM was 2.5 years in MPM-patients (range 0-16.6 years). Male gender, increasing age and high level of education were associated with a significantly higher risk of a second CMM (Table 2 ; Supporting Information Fig. S1 ). MPM-patients had a significantly higher T-class at diagnosis of their first CMM than SPM-patients (p 5 0.02; Table 3 ). The median tumor thickness was 1.1 mm (range 0.1-55 mm) for the first CMM in MPMs compared to 1.0 mm (range 0.1-123 mm; p 5 0.04) in SPMs ( Table 3 ). The median tumor thickness of the second CMM in MPMs was 0.7 mm (range 0.1-25 mm; p < 0.001; Table 3 ). The proportion of ulcerated tumors was lower for the second CMM than the first CMM in MPMs (Table 3; Supporting Information Table S1 ). Among the MPM-patients, the index CMM was the most advanced tumor in 68% (474/700 patients), p < 0.0001, (v 2 5 12.3, df 5 1), i.e., almost one third of the MPM-patients were diagnosed with more advanced subsequent CMM. Interestingly, 12.3% (86/700) of these subsequent tumors were NMs.
CMM-specific survival comparing MPM-with SPM-patients
The median time of follow-up for all patients was 8.6 years (range 0-23 years). The proportion of CMM-related deaths was significantly increased in patients with MPMs vs. SPMs (p 5 0.001).
The CMM-specific survival was analyzed by comparing MPM-with SPM-patients using survival time from the diagnosis of the second CMM and using the prognostic characteristics of the most advanced CMM for MPM-patients. In a Cox regression model, MPM-patients with 5 years interval between CMM diagnoses showed a trend towards an increased risk of CMM-specific death compared to SPM-patients in the fully adjusted analysis (HR 1.23; 95% CI 0.97-1.55; p 5 0.08; Table 4 , Fig. 1 ). There was no significant survival disadvantage for MPM patients with >5 years between the first and second CMM diagnosis (Table 4 , Fig. 1 ). The HR reached a significant level for MPM-vs. SPM-patients for patients with 2 CMMs (HR 1.29; 95% CI 1.01-1.65; p 5 0.04). Excluding patients with 3 CMMs did not have any impact on the survival analyses below. In the analysis of Stage I-II MPM-patients compared to SPM-patients, an interval of 5 years was significantly correlated to a decreased CMM-specific survival after full adjustments (HR 1.32; 95% CI 1.04-1.67; p 5 0.02; Table 4 ). When comparing within the MPM-group including all stages, a time interval of 5 years was significantly associated with worse CMM-specific survival in the fully adjusted model (HR 2.01; 95% CI 1.08-3.72; p 5 0.03; Table 4 ). By adding information on prognostic histopathological data from the more favorable tumor in addition to data from the most advanced CMM did not improve the multivariate models, p 5 0.09 (df 5 16, v 2 5 23.9).
The additional adverse effect of a second primary CMM on disease survival MPM-patients had a significantly reduced CMM-specific survival vs. SPM-patients from the diagnosis of the index CMM, specifically within Stage I, in the Kaplan-Meier analyses (p < 0.001; Supporting Information Fig. S2 ).
Using interval between the diagnosis of MPM vs. SPM as a time-dependent covariate, the risk of death from CMM increased significantly by almost 50% after a second CMM (HR 1.48; 95% CI 1.19-1.85; p < 0.001; Table 5 ). A sensitivity analysis was performed and excluding synchronous CMMs did not significantly change the results (HR 1.52; 95% CI 1.18-1.96). In a time-fixed approach adjusted based on the index CMM, a significantly elevated HR for CMM-specific death was found in MPMvs. SPM-patients (HR 1.38; 95% CI 1.05-1.83; p 5 0.001). Men with MPMs had a significantly decreased CMM-specific survival compared to male SPM-patients in the time-dependent analysis (HR 1.64; 95% CI 1.27-2.11; p interaction 5 0.22; Table 5 ). No prognostic difference between men and women was found. In patients 70 years, MPM-patients had a significantly increased risk of CMM-specific death vs. SPMs (HR 1.90; 95% CI 1.39-2.60; p interaction 5 0.07; Table 5 ).
Discussion
In this large nationwide population-based study, we could, for the first time, show for Stage I-II MPMs that an interval 5 years is associated with a significantly worse prognosis than for both SPM-patients and MPM-patients with a longer time interval, also confirmed within the MPM-group. Importantly, we demonstrated that the risk of CMM death increases by nearly 50% from the index CMM by the diagnosis of a second CMM. 
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The CMM-specific survival was significantly lower in MPMthan in SPM-patients. As the first study to date, we found a correlation between risk of CMM-related death and time interval between tumors comparing MPM-to SPM-patients with localized disease as well as within the MPM-group. A time interval of 5 years was associated with a worse prognosis, but with longer time interval (>5 years) the risk of death was comparable to that of the index CMM. For all MPMs vs. SPMs, a trend of decreased CMMspecific survival was correlated to an interval time between diagnoses 5 years but became significant for MPMs when excluding patients diagnosed with 3 CMMs. These findings together with the survival data described below may have implications for improved prevention strategies and follow-up of CMM-patients.
By using a time-dependent model, we observed that the risk of CMM-related death increased remarkably from baseline at the time of the second primary CMM. This implies that a second CMM adds risk of CMM-specific death to that of the index CMM. Clinically this would indicate that a patient diagnosed with a low-risk index CMM with a favorable CMMprognosis would have a significantly decreased expected CMM-survival by almost 50% if the patient is diagnosed with a second CMM. Our results are in line with the findings by Youlden et al.
14 who used a delayed-entry model to analyze the impact of MPMs on CMM-survival. Several previous studies have not detected significant differences in CMM-prognosis and even improved CMM specific survival has been associated with the MPM-group. 3, 5, 11, 12 The prognosis of MPMs is difficult to assess, being conditional on patients surviving the primary CMM. The deaths cannot be attributed unequivocally to the first or subsequent tumor considered by Rowe et al. 13 By indexing the first primary CMM in MPM-patients and not including analysis of survival time before the second CMM in MPM-patients, "guarantee time" may bias the results and contribute to overestimation of survival intervals. 3, 12, 14 To overcome such bias, we grouped all patients as SPM-patients until being diagnosed with a second CMM in the survival analyses. We found that using data on the most advanced CMM when assessing the risk of CMM death improved the analyses, but no additional effect was found when adding prognostic information from the less advanced tumors. Differences between previous reports on survival in MPM-compared to SPM-patients may also be attributed to considerable variations in sample size, study design, choice of index CMM and follow-up. 3, 5, [11] [12] [13] [14] In a time-fixed model, the CMM-survival was reduced in MPM-patients but to a lower extent in comparison with SPMpatients. These findings support our conclusion that MPMpatients experience a worse CMM-prognosis, in accordance with recent studies. 13, 14 We found that almost 3% of the patients developed MPMs which is a lower proportion compared to the findings in some previous studies. 6, 11, 12, 14, 15 In the patient cohort by Moore et al.,
15 7% developed MPMs. In analyses with in average 5 years longer follow-up than ours, the time of follow-up is therefore likely to explain these differences in proportion of MPMs between studies. 6, 11, 12, 14, 15 In addition, the present report included invasive CMMs as compared to for example Kricker et al.
11 that also analyzed in situ tumors. 
The median tumor thickness of the index CMM in MPMpatients in our study was thicker compared to patients with SPMs, which has previously been reported. 28, 29 These differences may imply a propensity among MPM-patients to develop more aggressive disease and could reflect a clustering of fatal CMMs with specific genetic aberrations. 30 However, more advanced T-class in MPM-patients could not explain the worse outcome in the present study, i.e., the HRs were not affected after adjusting for stage and tumor thickness. Moreover, we found that subsequent CMMs in the same individual were thinner than the index CMM, in line with previous findings. 3, 5, 6, 11, 12, 15 This may be a result of increased awareness and skin surveillance contributing to earlier detection, rather than differences in biologic tumor aggressiveness. 6, 31 Interestingly, the Australian study by Youlden et al. 14 reported a higher proportion of T1 primary invasive CMMs in MPM-patients compared to our data (68.5% vs. 47.4%, respectively). Furthermore, when comparing the second invasive tumor, the proportion of T1 tumors (70.5%) remained stable in Australian patients, while the corresponding proportion increased (67.9%) among the Swedish patients. This may indicate that an increased awareness or a positive effect of the follow-up visits among Swedish patients after having been diagnosed with a primary CMM.
On the other hand, one third of the patients in our study had a more advanced subsequent tumor compared to the index CMM. These CMMs were to a larger extent NMs which is in line with a more rapid development of vertical growth in NMs. We did not find any significant difference in histological parameters such as ulceration status between the index CMM in MPM-vs. SPM-patients. Likewise, Hwa et al. 6 did not find any difference in rate of mitoses in the index tumor between MPMs and SPMs. Previous data suggest gender-specific differences in relative risks of CMMdeath both in early and later stages of disease, but there is limited evidence for such differences in MPMs. 11, 32, 33 In our study, older and male MPM-patients seemed to have a worse CMM-specific survival than the corresponding groups with SPMs. The nonsignificant p values for the interactions terms for the sex difference (p 5 0.22) and with respect to age (p 5 0.07) suggest that these findings should be validated. However, men, older and highly educated individuals were at higher risk of developing a second CMM.
The strengths of our study include a large nationwide population-based cohort with a complete follow-up and prospectively collected data on multiple prognostic variables. Missing information on stage at diagnosis was significantly associated with two of the health care regions and was due to a later start of registration and was regarded as due to delayed registration resulting in shorter follow-up of patient cohorts from these two regions. The Cox analyses were adjusted for time-period and stratified for health care region
In conclusion, we showed that patients diagnosed with MPMs experienced a significantly reduced CMM-specific survival compared to SPM-patients. We report, for the first time, that the CMM-specific prognosis in Stage I-II MPMs compared to SPMs as well within the MPM-group is negatively influenced by a short time interval, 5 years, between diagnoses, in contrast to patients with longer intervals. The risk of CMM-specific death increased by nearly 50% above the expected outcome of the index CMM by the diagnosis of a second CMM. By analyzing different aspects of CMM prognosis in MPM-patients, our findings emphasize the importance not only of prevention in SPM-patients to decrease the risk of subsequent CMMs, but also have implications for more vigilant follow-up in MPM-patients, due to the worse CMM-specific prognosis.
